Abstract
[Objective] To evaluate calprotectin, hypersensitive C-reactive protein, and interleukin-6 for detecting digestive tract mucosal injury in Crohn's disease (CD) patients.
[Methods] 52 patients diagnosed with CD were selected. Fecal samples from the patients were collected to detect calprotectin (ELISA), and serum samples were collected to detect hs-CRP (Immunoturbidimetry) and IL-6 (Chemiluminescence). All patients with CD underwent colonoscopy or capsule endoscopy. According to the modified endoscopic severity index of CD (SES-CD). Comparisons were made between the two groups' variations in calprotectin, hs-CRP, and IL-6 levels, and ROC curves were drawn to analyze the diagnostic efficacy (AUC) of each index and combined detection for mucosal injury.
[Results] In the Mucosal injury group, the calprotectin, hs-CRP levels were significantly greater than those in the mucosal healing group. Calprotectin had the highest AUC (0.93, 95% CI: 0.88–0.98), sensitivity (88.5%), and specificity (89.2%) when the critical value was greater than 250μg/g, according to ROC analysis. The AUC of the three indicators' combined detection (logistic regression model) rose to 0.96, which was noticeably superior than that of a single indicator (P<0.05).
[Conclusion] Interleukin-6, serum calprotectin, and hypersensitive C-reactive protein levels are significantly correlated with the degree of mucosal injury in patients with CD. Among them, calprotectin has the best diagnostic value. The combined detection of these three factors can significantly improve the recognition of mucosal injury in the active stage of CD.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.